{
  "pmcid": "10527167",
  "pmid": "37334719",
  "title": "Patient-Reported Adverse Events during Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)",
  "abstract": "Objective:: We sought to evaluate symptomatic adverse event (AE) rates among patients with pancreatic cancer receiving neoadjuvant therapy on clinical trial (A021501) using the Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE).\n\nSummary Background Data:: To date, pancreatic cancer clinical trials have measured AEs using standard physician reporting (CTCAE). Patient-reported symptomatic AEs have been incompletely characterized.\n\nMethods:: A021501 (Dec 31, 2016-Jan 1, 2019) randomized patients with borderline resectable pancreatic ductal adenocarcinoma to 8 doses of mFOLFIRINOX (Arm 1) or 7 doses of mFOLFIRINOX + hypofractionated radiotherapy (Arm 2), followed by pancreatectomy and adjuvant FOLFOX6. Patients completed PRO-CTCAE assessments at baseline, on day 1 of each chemotherapy cycle, and daily during radiotherapy.\n\nResults:: Of 126 patients, 96 (76%) initiated treatment and completed a baseline plus at least 1 post-baseline PRO-CTCAE assessment. Diarrhea and fatigue were the only symptomatic grade 3 or higher AEs identified in at least 10% of patients using CTCAE. At least 10% of all patients reported an adjusted PRO-CTCAE composite grade 3 AE during neoadjuvant treatment for 10 of 15 items: anxiety (10%), bloating of abdomen (16%), decreased appetite (18%), diarrhea (13%), dry mouth (21%), fatigue (36%), nausea (18%), generalized pain (16%), abdominal pain (21%), and problems tasting (32%). Decreased appetite was higher in Arm 2 than in Arm 1 ( P =0.0497); no other differences between study arms were observed.\n\nConclusions:: Symptomatic AEs during neoadjuvant therapy were common and were reported more frequently by patients using PRO-CTCAE than were recorded by clinicians using standard CTCAE.\n\nMINI-ABSTRACT: We sought to evaluate patient-reported symptomatic adverse event rates among patients with borderline-resectable pancreatic cancer receiving neoadjuvant therapy on clinical trial (A021501). Symptomatic adverse events during neoadjuvant therapy were common and were reported more frequently by patients compared to standard clinician reporting.",
  "authors": [
    "Rebecca A. Snyder",
    "Amylou C. Dueck",
    "Briant Fruth",
    "Qian Shi",
    "Joleen M. Hubbard",
    "Joseph M. Herman",
    "Eileen M. Oâ€™Reilly",
    "Matthew H.G. Katz"
  ],
  "journal": "Annals of surgery",
  "year": "2023",
  "full_text": "",
  "pdf_url": "",
  "pdf_downloaded": false,
  "pdf_embedded_viewer": false
}